Gastric Emptying Modulation GLP2 transiently delays gastric emptying, similar to selective GLP-1 receptor agonists: Slowed rate of nutrient absorption from the gastrointestinal tract Reduced postprandial glucose excursions Effect is most pronounced after initial doses and diminishes with continued treatment Contributes to improved glycemic control through multiple complementary mechanisms Central Nervous System Effects Appetite Regulation Both GIP and GLP-1 receptors are expressed in brain regions controlling appetite and food intake: Reduced food intake and appetite through central nervous system receptor activation Promotion of satiety signals leading to decreased caloric consumption Potential modulation of reward-related feeding behaviors Weight loss effects that appear mediated through both homeostatic and hedonic feeding pathways Clinical trials have demonstrated substantial weight reduction, with participants experiencing decreased appetite as a commonly reported effect of GLP2 treatment
Many patients find semaglutide gentler because its digestion changes develop more gradually
Degraded peptides deliver unpredictable results and can be unsafe
It is important to note that the drugs themselves are not the cause of improved fertility
Store tirzepatide in a refrigerator at 28C in its original carton to protect from light
3.3 Tirzepatide effects: cardiovascular, renal, hepatic, and other metabolic effects of tirzepatide Due to concerns that type 2 diabetes medications increased cardiovascular risk, the FDA issued guidance for pharmaceutical companies to perform cardiovascular outcomes trials for new diabetes medications
